Merck Canada

/Products/

PRESCRIPTION PRODUCTS

All Products A-Z

A – G H – O P – Z

A – G

BELSOMRA^®

BRIDION^®

CANCIDAS^®

DELSTRIGO^®

DIFICID^®

EMEND^®

EMEND^®IV

H – O

INTEGRILIN^®

Product Monograph Feb-2011

INTRON A^®

INVANZ^®

ISENTRESS^®

ISENTRESS HD^®

JANUMET^®

JANUMET^®XR

JANUVIA^®

KEYTRUDA^®

OncoTICE^®

P – Z

PIFELTRO^®

POSANOL^®

PREVYMIS^®

PRIMAXIN^®

PRINIVIL^®

PROGLYCEM^®

Product Monograph Apr-2015

SEGLUROMET ^TM

STEGLATRO^TM

STROMECTOL^TM

TEMODAL^®

ZEPATIER^®

ZERBAXA^®

ZOLINZA^®

These files are presented in PDF format. This software is available at no charge through the Adobe Web site. Get Adobe Reader

DISCLAIMER

The contents of this site, including but not limited to Merck product information and product monographs, are for informational purposes only and are intended solely for residents of Canada, and are not intended, nor should they be used, as a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician, pharmacist or other qualified health care provider with any questions you may have regarding a medical condition.
--------------------------------------------------------------------------------
®/TM Trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., or its affiliates. Used under license.

For Healthcare Professionals Only.

Learn more

For Canadian Health Care Professionals

To ask medical questions, report adverse experiences or product complaints, or to provide comments on any Merck Canada Inc. product, please contact our Medical Information Centre:
medinfocanada@merck.com

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

PRESCRIPTION PRODUCTS

BELSOMRA®

BRIDION®

CANCIDAS®

DELSTRIGO®

DIFICID®

EMEND®

EMEND®IV

INTEGRILIN®

INTRON A®

INVANZ®

ISENTRESS®

ISENTRESS HD®

JANUMET®

JANUMET®XR

JANUVIA®

KEYTRUDA®

OncoTICE®

PIFELTRO®

POSANOL®

PREVYMIS®

PRIMAXIN®

PRINIVIL®

PROGLYCEM®

SEGLUROMET TM

STEGLATROTM

STROMECTOLTM

TEMODAL®

ZEPATIER®

ZERBAXA®

ZOLINZA®

​For Healthcare Professionals Only.